What type of study is this?

This is a Literature Review study.

September 12, 2025Frontiers in Oncology0 citationsOpen Access

Head and neck cancer – emerging targeted therapies

Key Points

Recent therapies exhibit promise for recurrent head and neck cancer, indicating a shift towards targeted treatments.
Current therapies primarily include platinum combinations and anti-PD-1 agents, revealing a need for novel options.
Emerging agents feature new mechanisms like bi-specific antibodies, emphasizing innovation in treatment strategies.
Exploration of ongoing clinical trials suggests potential breakthroughs in managing metastatic head and neck cancer.

Abstract

Systemic therapy remains the cornerstone of treatment for recurrent and metastatic (R/M) head and neck squamous cell cancers (HNSCC). However, there is a dearth of effective treatments beyond platinum combinations, anti-programmed death-1 (PD-1) agents and the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody cetuximab. Recent years have seen several exciting new agents being tested in clinical trials. These are designed to target alternate oncogenic signaling pathways and have novel mechanistic compositions, including bi-specific antibodies and antibody-drug conjugates. This review will delve into the clinical limitations of currently approved systemic therapies, explore newer agents in development and highlight ongoing clinical trials using targeted therapies in this disease.

KI fragen

Bookmark

View Full Paper